Summary | |
---|---|
Symbol | CYP1A2 |
Name | cytochrome P450, family 1, subfamily A, polypeptide 2 |
Aliases | P3-450; CP12; cytochrome P450, subfamily I (aromatic compound-inducible), polypeptide 2; P450(PA); CYPIA2; P ...... |
Chromosomal Location | 15q24.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Endoplasmic reticulum membrane; Peripheral membrane protein. Microsome membrane Peripheral membrane protein. |
Domain |
PF00067 Cytochrome P450 |
Function |
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N3-demethylation. Also acts in the metabolism of aflatoxin B1 and acetaminophen. Participates in the bioactivation of carcinogenic aromatic and heterocyclic amines. Catalizes the N-hydroxylation of heterocyclic amines and the O-deethylation of phenacetin. |
Biological Process |
GO:0001676 long-chain fatty acid metabolic process GO:0002237 response to molecule of bacterial origin GO:0006091 generation of precursor metabolites and energy GO:0006631 fatty acid metabolic process GO:0006690 icosanoid metabolic process GO:0006706 steroid catabolic process GO:0006720 isoprenoid metabolic process GO:0006721 terpenoid metabolic process GO:0006778 porphyrin-containing compound metabolic process GO:0006805 xenobiotic metabolic process GO:0008202 steroid metabolic process GO:0009403 toxin biosynthetic process GO:0009404 toxin metabolic process GO:0009410 response to xenobiotic stimulus GO:0009791 post-embryonic development GO:0009820 alkaloid metabolic process GO:0010035 response to inorganic substance GO:0010038 response to metal ion GO:0015980 energy derivation by oxidation of organic compounds GO:0016042 lipid catabolic process GO:0016098 monoterpenoid metabolic process GO:0017144 drug metabolic process GO:0018894 dibenzo-p-dioxin metabolic process GO:0019369 arachidonic acid metabolic process GO:0019373 epoxygenase P450 pathway GO:0019748 secondary metabolic process GO:0030323 respiratory tube development GO:0030324 lung development GO:0032259 methylation GO:0032355 response to estradiol GO:0032496 response to lipopolysaccharide GO:0033013 tetrapyrrole metabolic process GO:0033559 unsaturated fatty acid metabolic process GO:0035902 response to immobilization stress GO:0042493 response to drug GO:0042737 drug catabolic process GO:0042738 exogenous drug catabolic process GO:0042743 hydrogen peroxide metabolic process GO:0044550 secondary metabolite biosynthetic process GO:0045333 cellular respiration GO:0046686 response to cadmium ion GO:0050665 hydrogen peroxide biosynthetic process GO:0051186 cofactor metabolic process GO:0060541 respiratory system development GO:0070988 demethylation GO:0070989 oxidative demethylation GO:0071241 cellular response to inorganic substance GO:0071248 cellular response to metal ion GO:0071276 cellular response to cadmium ion GO:0071466 cellular response to xenobiotic stimulus GO:0071615 oxidative deethylation GO:0072593 reactive oxygen species metabolic process GO:0097267 omega-hydroxylase P450 pathway GO:1901361 organic cyclic compound catabolic process GO:1903409 reactive oxygen species biosynthetic process |
Molecular Function |
GO:0004497 monooxygenase activity GO:0005506 iron ion binding GO:0009055 electron carrier activity GO:0016705 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016712 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen GO:0016725 oxidoreductase activity, acting on CH or CH2 groups GO:0019825 oxygen binding GO:0020037 heme binding GO:0032451 demethylase activity GO:0033695 oxidoreductase activity, acting on CH or CH2 groups, quinone or similar compound as acceptor GO:0034875 caffeine oxidase activity GO:0046906 tetrapyrrole binding GO:0070330 aromatase activity |
Cellular Component | - |
KEGG |
hsa00140 Steroid hormone biosynthesis hsa00232 Caffeine metabolism hsa00380 Tryptophan metabolism hsa00591 Linoleic acid metabolism hsa00830 Retinol metabolism hsa00980 Metabolism of xenobiotics by cytochrome P450 hsa00982 Drug metabolism - cytochrome P450 hsa01100 Metabolic pathways |
Reactome |
R-HSA-5423646: Aflatoxin activation and detoxification R-HSA-2142753: Arachidonic acid metabolism R-HSA-211957: Aromatic amines can be N-hydroxylated or N-dealkylated by CYP1A2 R-HSA-211859: Biological oxidations R-HSA-211897: Cytochrome P450 - arranged by substrate type R-HSA-1430728: Metabolism R-HSA-556833: Metabolism of lipids and lipoproteins R-HSA-156581: Methylation R-HSA-211945: Phase 1 - Functionalization of compounds R-HSA-156580: Phase II conjugation R-HSA-2142816: Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE) R-HSA-2142670: Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET) R-HSA-211981: Xenobiotics |
Summary | |
---|---|
Symbol | CYP1A2 |
Name | cytochrome P450, family 1, subfamily A, polypeptide 2 |
Aliases | P3-450; CP12; cytochrome P450, subfamily I (aromatic compound-inducible), polypeptide 2; P450(PA); CYPIA2; P ...... |
Chromosomal Location | 15q24.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between CYP1A2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | CYP1A2 |
Name | cytochrome P450, family 1, subfamily A, polypeptide 2 |
Aliases | P3-450; CP12; cytochrome P450, subfamily I (aromatic compound-inducible), polypeptide 2; P450(PA); CYPIA2; P ...... |
Chromosomal Location | 15q24.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of CYP1A2 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | CYP1A2 |
Name | cytochrome P450, family 1, subfamily A, polypeptide 2 |
Aliases | P3-450; CP12; cytochrome P450, subfamily I (aromatic compound-inducible), polypeptide 2; P450(PA); CYPIA2; P ...... |
Chromosomal Location | 15q24.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of CYP1A2 in various data sets.
|
Points in the above scatter plot represent the mutation difference of CYP1A2 in various data sets.
|
Summary | |
---|---|
Symbol | CYP1A2 |
Name | cytochrome P450, family 1, subfamily A, polypeptide 2 |
Aliases | P3-450; CP12; cytochrome P450, subfamily I (aromatic compound-inducible), polypeptide 2; P450(PA); CYPIA2; P ...... |
Chromosomal Location | 15q24.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CYP1A2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | CYP1A2 |
Name | cytochrome P450, family 1, subfamily A, polypeptide 2 |
Aliases | P3-450; CP12; cytochrome P450, subfamily I (aromatic compound-inducible), polypeptide 2; P450(PA); CYPIA2; P ...... |
Chromosomal Location | 15q24.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CYP1A2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CYP1A2. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | CYP1A2 |
Name | cytochrome P450, family 1, subfamily A, polypeptide 2 |
Aliases | P3-450; CP12; cytochrome P450, subfamily I (aromatic compound-inducible), polypeptide 2; P450(PA); CYPIA2; P ...... |
Chromosomal Location | 15q24.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CYP1A2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | CYP1A2 |
Name | cytochrome P450, family 1, subfamily A, polypeptide 2 |
Aliases | P3-450; CP12; cytochrome P450, subfamily I (aromatic compound-inducible), polypeptide 2; P450(PA); CYPIA2; P ...... |
Chromosomal Location | 15q24.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of CYP1A2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | CYP1A2 |
Name | cytochrome P450, family 1, subfamily A, polypeptide 2 |
Aliases | P3-450; CP12; cytochrome P450, subfamily I (aromatic compound-inducible), polypeptide 2; P450(PA); CYPIA2; P ...... |
Chromosomal Location | 15q24.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between CYP1A2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | CYP1A2 |
Name | cytochrome P450, family 1, subfamily A, polypeptide 2 |
Aliases | P3-450; CP12; cytochrome P450, subfamily I (aromatic compound-inducible), polypeptide 2; P450(PA); CYPIA2; P ...... |
Chromosomal Location | 15q24.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting CYP1A2 collected from DrugBank database. |
Details on drugs targeting CYP1A2.
|